DEXAMETHASONE | N013538 | MERCK AND CO INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | NYU Langone Health | 1,300 | 2020-08-01 → 2029-06-30 | |
| Phase 2 | Active | University of Arkansas | 50 | 2017-07-01 → 2028-10 | |
| Phase 3 | Active | Sanofi | 531 | 2022-06-23 → 2027-10-22 | |
| Phase 1 | Active | National Cancer Institute (NCI) | 24 | 2022-08-03 → 2028-06-30 | |
| Phase 1/2 | Active | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2019-02-12 → 2025-06-30 | |
| Phase 3 | Active | Janssen Research & Development, LLC | 587 | 2021-10-14 → 2028-09-15 | |
| Phase 2 | Active | Emory University | 49 | 2019-07-03 → 2026-07-31 | |
| Phase 1/2 | Active | Wake Forest University Health Sciences | 70 | 2021-05-19 → 2032-11 | |
| Phase 3 | Active | AbbVie | 421 | 2024-05-19 → 2027-12 | |
| Phase 3 | Active | University of Heidelberg Medical Center | 662 | 2018-10-18 → 2028-06 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
9 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.